Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cautious Roche Stresses: 'It's Not Only About APHINITY'

Executive Summary

Roche is suddenly sounding less optimistic about its Phase III APHINITY trial of Perjeta in the neoadjuvant breast cancer setting – stressing that 2017 will also bring three other key readouts for the company.

You may also be interested in...



Roche Relief As APHINITY Trial Boosts Outlook On Its Oncology Business

Roche released positive headlines from its APHINITY trial examining use of Herceptin and Perjeta together in the adjuvant treatment of breast cancer, offering promise that its aging oncology franchise can be protected.

Pressure On Tecentriq: Bladder Cancer Heats Up With Opdivo Approval, Keytruda Filing

Merck's filings in bladder cancer span first-line and second-line treatment and include overall survival data. Roche also is getting ready to move Tecentriq to the frontline setting.

Genentech’s Tecentriq Stakes New Claim With FDA Lung Cancer Approval

Genentech’s PD-L1 inhibitor Tecentriq could steal market share from the PD-1 inhibitors Opdivo and Keytruda in its new indication, but the Roche subsidiary’s drug is a year behind competitors from Bristol-Myers and Merck in NSCLC with seven Phase III trials under way to expand its reach in lung cancer.

Topics

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel